|
KMID : 1039120220110020184
|
|
Clinical and Experimental Vaccine Research
2022 Volume.11 No. 2 p.184 ~ p.192
|
|
|
Nasal vaccine as a booster shot: a viable solution to restrict pandemic?
|
|
Meenakshi Sarasa
Kumar V. Udaya
Dhingra Sameer
Murti Krishna
|
|
|
Abstract
|
|
|
|
The coronavirus disease 2019 (COVID-19) pandemic revolutionized the vaccine market and initiated the momentum for alternative routes of administration for vaccines. The intranasal route of immunization is one such possibility that appears to be the most promising since it has some significant advantages, particularly in the prevention of respiratory infection. To analyze and summarize the role of nasal vaccines over conventional vaccines during COVID-19 and the need for the nasal vaccine as a booster shot. In this narrative review, the required data was retrieved using keywords “COVID-19,” “Intranasal,” “Immunity,” “Nasal spray,” and “Mucosal” in databases including PubMed, Scopus, Embase, Science Direct, and Web of Sciences. The results of the study showed that the nasal vaccines were both effective and protective according to the current researches approaching during the COVID-19 period and the preclinical and clinical phase trials prove the intranasal vaccination elicits more robust and cross-protective immunity than conventional vaccines. In this narrative review article, mechanisms across the nasal mucosa will be briefly presented and the current status of nasal vaccines during the COVID-19 pandemic is summarized, and advantages over traditional vaccines are provided. Furthermore, after exploring the primary benefits and kinetics of nasal vaccine, the potential for consideration of nasal vaccine as a booster dose is also discussed.
|
|
|
KEYWORD
|
|
|
Nasal sprays, COVID-19, Immunity, Nasal cavity, Nasal vaccine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|